Loading clinical trials...
Loading clinical trials...
Phase II Clinical Trial of Mezigdomide/Carfilzomib/Dexamethasone (MeziKD) in Patients With Relapsed or Refractory Multiple Myeloma (MM) With Extramedullary Disease (EMD)
Conditions
Interventions
Mezigdomide
Carfilzomib
+8 more
Locations
1
United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Start Date
May 1, 2025
Primary Completion Date
May 1, 2027
Completion Date
May 1, 2030
Last Updated
January 12, 2026
NCT04973605
NCT06138275
NCT05862012
NCT06285318
NCT07391657
NCT07284758
Lead Sponsor
Roswell Park Cancer Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions